Marginal Zone Lymphoma treatment market is projected at a significant CAGR of 6.05% during the forecast period (2021-2030), as per DelveInsight
LAS VEGAS, Feb. 9, 2021 /PRNewswire/ -- DelveInsight's "Marginal Zone Lymphoma (MZL) Market" report provides a complete comprehension of the Marginal Zone Lymphoma, historical and forecasted epidemiology and the MZL market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Marginal Zone Lymphoma market report also proffers an analysis of recent MZL treatment practice/algorithm, market drivers, market barriers and unmet medical needs.
https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
Some of the highlights of Marginal Zone Lymphoma Market Research Report
-- In May 2019, the FDA approved lenalidomide (Revlimid) in combination
with a rituximab product for previously treated follicular lymphoma (FL)
and previously-treated MZL. Moreover, in December 2019, the European
Commission approved Revlimid (lenalidomide) combined with rituximab to
treat adult patients with previously treated Marginal Zone Lymphoma. The
drug is not being approved in Japan but is expected to get launched in
the forecast period 2020-2030 and hence is an emerging therapy for
Japan.
-- Imbruvica (ibrutinib) by AbbVie/Janssen Biotech is a first-in-class,
oral, once-daily therapy that inhibits a protein called Bruton's
tyrosine kinase (BTK). In January 2017, the USFDA approved Imbruvica
(ibrutinib) for the treatment of patients with relapsed/refractory (R/R)
Marginal Zone Lymphoma, who require systemic therapy and have received
at least one prior anti-CD20-based therapy.
-- Marginal Zone Lymphoma market is expected to grow due to factors like an
increase in the patient pool, expected entry of emerging therapies such
as Ublituximab, Duvelisib, Umbralisib (TGR-1202), and deeper penetration
in the 7MM.
-- Several pharmaceutical key players such as TG Therapeutics, Bayer, Roche
Pharma, Gilead Sciences, Merck, Cellectar Biosciences, Innovent
Biologics, Bristol-Myers Squibb, AstraZeneca, Nordic Nanovector, AbbVie,
InnoCare Pharma, ArQule, Verastem, Secura Bio, BeiGene, MEI Pharma,
NantKwest, ImmunityBio, Loxo Oncology, Eli Lilly, TriSalus Life
Sciences, and many others have taken the initiatives to meet the unmet
needs of the present situation of the MZL market.
For additional information on Market Impact by Therapies, visit: Marginal Zone Lymphoma Market Forecast Analysis
Marginal Zone B-cell lymphoma is a group of indolent Non-Hodgkin lymphoma (NHL) B-cell lymphomas that account for approximately 5?17% of all NHL cases. The total Non-Hodgkin lymphoma incident population in the 7MM was estimated to be 174,941 in 2020. Out of these, the total Marginal Zone Lymphoma incident population in the 7MM was 22,268 in the same year.
The Marginal Zone Lymphoma Market Report provides historical as well as forecasted epidemiological analysis segmented into:
-- Total incident cases of Non-Hodgkin lymphoma (NHL)
-- Total incident cases of Marginal Zone Lymphoma (MZL)
-- Gender-specific incident cases of MZL
-- Subtype-specific incident cases of MZL
-- Stage-specific incident cases of MZL
Review a sample report for more insights @ Marginal Zone Lymphoma Market Insight
Marginal Zone Lymphoma Treatment Market
Treatment selection for an MZL patient depends on the type, stage, and location of the disease. The total MZL market is categorized into three types based on the line of therapies, first-line, second-line, and third-line of therapies. The first line treatment comprises only the supportive therapies, including rituximab monotherapy, R-CHOP/R-CVP, rituximab plus bendamustine, cytotoxic chemotherapy, antiviral therapy for hepatitis C infection, Antibiotic/PPIs.
In May 2019, the FDA approved lenalidomide (Revlimid) combined with a rituximab product for previously treated follicular lymphoma (FL) and previously-treated MZL. Moreover, in December 2019, the European Commission approved Revlimid (lenalidomide) in combination with rituximab for the treatment of adult patients with previously treated MZL. The drug is not being approved in Japan but is expected to get launched in the forecast period 2020-2030 and hence is an emerging therapy for Japan.
Revlimid is an immune-modulating therapy with proven anti-myeloma e?ects. The drug is an oral therapy that was shown to work in 3 ways in animal models and in vitro, it aids the immune system to identify and eradicate myeloma cells. It targets and destroys myeloma cells and helps prevent new myeloma cell growth by starving them of blood.
Several pharmaceutical key players have taken the initiatives to meet the unmet needs of the present situation of the MZL market. Some of the key players are in the late and mid clinical development stages with their leading drug candidates. MZL pipeline possesses potential drugs as monotherapies as well as combination therapies.
Marginal Zone Lymphoma Emerging Therapies Along with Key Players
-- Umbralisib (TGR-1202): TG Therapeutics
-- Aliqopa (Copanlisib): Bayer
-- Ublituximab: TG Therapeutics
-- Obinutuzumab: Roche Pharma
-- Yescarta (axicabtagene ciloleucel): Gilead Sciences
-- Keytruda (Pembrolizumab): Merck Sharp & Dohme
-- CLR 131: Cellectar Biosciences
-- Parsaclisib: Innovent Biologics
-- Nivolumab (Opdivo): Bristol-Myers Squibb
-- Calquence (acalabrutinib): Astrazeneca
-- Betalutin (177Lu-satetraxetan-lilotomab): Nordic Nanovector
-- Navitoclax (ABT-263): AbbVie
-- Orelabrutinib (ICP-022): InnoCare Pharma
-- M7583: Merck KGaA
-- ARQ 531: ArQule/Merck
-- Duvelisib: Verastem/Secura Bio
-- Zanubrutinib: BeiGene
-- Zandelisib: MEI Pharma
-- ALT-803: NantKwest/ImmunityBio
-- LOXO-305: Loxo Oncology/Eli Lilly
-- SD-101: TriSalus Life Sciences
And several others.
Concluding thoughts on Marginal Zone Lymphoma Market Growth
Marginal Zone Lymphoma Market Drivers
-- Awareness about the disease - Increased public awareness creates a
lucrative opportunity to innovate therapeutics to drive MZL market.
-- The rise in MZL cases - A better understanding of each subtype's
molecular events is increasing day by day.
-- Research and development - Growing research and development increase the
demand for better diagnosis and MZL treatment options.
-- Pipeline Advancement - A large number of agents are showing promising
activity in MZL because of recent advances in a better understanding of
the drug.
Marginal Zone Lymphoma Market Barriers
-- Diagnostic challenges - Some patients develop resistance to the drug
rituximab and do not respond well to the therapy. Diagnostic options are
much needed to improve the Marginal Zone Lymphoma prognosis and outcomes
for patients.
-- Adverse effects of current treatment - The drugs are hampered by
specific adverse effects coupled with patent expiration. Splenectomy and
chemoimmunotherapy used in the treatment of MZL bear increased risks of
complications in older patients.
Scope of the Marginal Zone Lymphoma Market Insight
-- Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy,
Spain, and the United Kingdom), Japan
-- Study Period: 4-year historical and 10-year forecasted analysis
(2017-2030)
-- Marginal Zone Lymphoma Markets Segmentation: By Geographies and By
Marginal Zone Lymphoma Therapies (Historical and Forecasted, Current and
Upcoming)
-- Leading Companies investigating its candidates for Marginal Zone
Lymphoma: TG Therapeutics, Bayer, Roche Pharma, Gilead Sciences, Merck,
Cellectar Biosciences, Innovent Biologics, Bristol-Myers Squibb,
AstraZeneca, Nordic Nanovector, AbbVie, InnoCare Pharma, ArQule,
Verastem, Secura Bio, BeiGene, MEI Pharma, NantKwest, ImmunityBio, Loxo
Oncology, Eli Lilly, TriSalus Life Sciences, and several others.
-- Analysis: Comparative and conjoint analysis of emerging therapies,
Attribute Analysis
-- Case Studies
-- KOL's Views
-- Analyst's View
Request for a Webex demo of the report @ Marginal Zone Lymphoma Market Size
Table of Contents
1 Key Insights on
Marginal Zone Lymphoma
---
2 Executive Summary of
Marginal Zone Lymphoma
---
3 Marginal Zone Lymphoma Market Overview at a Glance
---
4 Disease Background and Overview: Marginal Zone Lymphoma
---
5
Marginal Zone Lymphoma Case Reports
---
6 MZL Epidemiology and Patient Population
---
6.1
United States
---
6.2
EU5 Countries
---
6.2.1
Germany
---
6.2.2
France
---
6.2.3
Italy
---
6.2.4
Spain
---
6.2.5
United Kingdom
---
6.3
Japan
---
7 Current
Marginal Zone Lymphoma Treatment and
Medical Practices
---
8
Marginal Zone Lymphoma Unmet Needs
---
9 Marginal Zone Lymphoma Marketed Drugs
---
9.1 Revlimid (lenalidomide) in combination with rituximab:
Celgene Corporation, Bristol-Myers Squibb
---
9.2
Imbruvica (ibrutinib): AbbVie, Janssen Biotech
---
10 Marginal Zone Lymphoma Emerging Drugs
---
10.1
Key Cross Competition
---
10.2
Umbralisib (TGR-1202): TG Therapeutics
---
10.3
Aliqopa (Copanlisib): Bayer
---
10.4
Ublituximab: TG Therapeutics
---
10.5
Obinutuzumab: Roche Pharma
---
10.6 Yescarta (axicabtagene ciloleucel): Gilead Sciences
---
10.7
Keytruda (Pembrolizumab): Merck Sharp & Dohme
---
10.8
CLR 131: Cellectar Biosciences
---
10.9
Parsaclisib: Innovent Biologics
---
10.10
Nivolumab (Oppdivo): Bristol-Myers Squibb
---
10.11
Calquence (acalabrutinib): Astrazeneca
---
10.12 Betalutin (177Lu-satetraxetan-lilotomab): Nordic
Nanovector
---
10.13
Navitoclax (ABT-263): AbbVie
---
10.14
Orelabrutinib (ICP-022): InnoCare Pharma
---
10.15
M7583: Merck KGaA
---
10.16
ARQ 531: ArQule/Merck
---
10.17
Duvelisib: Verastem/Secura Bio
---
10.18
Zanubrutinib: BeiGene
---
10.19
Zandelisib: MEI Pharma
---
10.20
ALT-803: NantKwest/ImmunityBio
---
10.21
LOXO-305: Loxo Oncology/Eli Lilly
---
10.22
SD-101: TriSalus Life Sciences
---
11
MZL Patient Journey
---
12 7MM
Marginal Zone Lymphoma Market Analysis
---
13
Potential of MZL Emerging Therapies
---
14 Key
Marginal Zone Lymphoma Market Forecast
Assumptions
---
15
United States MZL Market Outlook
---
16
EU-5 MZL Market Outlook
---
16.1
Germany Market Size
---
16.2
France Market Size
---
16.3
Italy Market Size
---
16.4
Spain Market Size
---
16.5
United Kingdom Market Size
---
17
Japan MZL Market Outlook
---
18 Marginal Zone Lymphoma Market Drivers
---
19 Marginal Zone Lymphoma Market Barriers
---
20 Reimbursement and
Marginal Zone Lymphoma
Market Access
---
21
Recognized Establishments
---
22
Appendix
---
23
DelveInsight Capabilities
---
24
Disclaimer
---
25
About DelveInsight
---
Browse detailed TOC with charts, figures, tables @ Marginal Zone Lymphoma Therapeutic Market
View Related Reports
-- Marginal Zone Lymphoma Epidemiology Forecast Analysis
DelveInsight's Marginal Zone Lymphoma - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology.
-- Morquio Syndrome Market Analysis
DelveInsight's Morquio Syndrome Market Insights, Epidemiology and Market Forecast - 2030 report provides detailed insights on historical and forecasted epidemiology.
-- Diabetes Market Analysis
DelveInsight's Diabetes Market Insights, Epidemiology and Market Forecast - 2030 report provides thorough insights on epidemiology and market trends.
-- Buerger's Disease Market Analysis
DelveInsight's Buerger's Disease Market Insights, Epidemiology and Market Forecast - 2030 report provides thorough insights on epidemiology and market trends.
-- Multiple Sclerosis Market Analysis
DelveInsight's Multiple Sclerosis- Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed understanding of historical and forecasted epidemiology.
-- Chronic Wounds Market
DelveInsight's Chronic Wounds Market Insights, Epidemiology and Market Forecast - 2030 report provides detailed insights on historical and forecasted epidemiology.
-- Smoking Cessation Market Analysis
DelveInsight's Smoking Cessation - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
-- Radiation Toxicity Market Analysis
DelveInsight's Radiation Toxicity Market Insights, Epidemiology and Market Forecast - 2030 report provides an in-depth understanding of historical and forecasted epidemiology.
-- Indolent Lymphoma Market Analysis
DelveInsight's Indolent Lymphoma - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology.
-- ICOS-Next Generation Immunotherapy Competitive Landscape and Market
Forecast Analysis
DelveInsight's 'ICOS-Next Generation Immunotherapy- Competitive Landscape and Market Forecast-2035' report delivers an in-depth understanding of the ICOS as well as the market trends.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Contact Us:
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
View original content:http://www.prnewswire.com/news-releases/marginal-zone-lymphoma-treatment-market-is-projected-at-a-significant-cagr-of-6-05-during-the-forecast-period-2021-2030-as-per-delveinsight-301224945.html
SOURCE DelveInsight Business Research, LLP
